Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, , Dec. 31, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABEO) today announced it has granted equity awards to new ...
The Pharma Letter9d
City Therapeutics appoints Andrew Orth as chief exec
City Therapeutics appoints Andrew Orth as CEO, leveraging his expertise in RNA and gene therapies as the company advances its ...
Frontiers10d
Advancements in bioengineered and autologous skin grafting techniques for skin reconstruction: a comprehensive review
The reconstruction of complex skin defects challenges clinical practice, with autologous skin grafts ... was successfully used in a newborn with the Dowling-Meara variant of epidermolysis bullosa (EB) ...
INmune Bio treatment of epidermolysis bullosa receives FDA orphan designation
INmune Bio’s (INMB) treatment of epidermolysis bullosa received FDA orphan designation, according to a post on the agency’s site.Don't Miss Our ...
Morningstar10d
Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study
Highly Positive Clinical Data on Completion of Testing ... Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn ...
The Victoria Advocate3d
Exosome Therapies Market Poised for Explosive Growth During the Study Period (2025-2034) | DelveInsight
Several therapies are presently in the pre-clinical development phase for ... models to stimulate Recessive Dystrophic Epidermolysis Bullosa (RDEB) cells, which cannot produce COL7, to generate ...
Morningstar29d
Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies
Clinical Data from First Subject Dosed Twice ... Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for ...
pharmaphorum2d
FDA clears Vyjuvek as first topical gene therapy
The FDA has approved Krystal Biotech’s gene therapy Vyjuvek for dystrophic epidermolysis bullosa (DEB), a rare ... who live far from specialised clinical centres. In the 31-patient GEM-3 ...
Nasdaq29d
Krystal Biotech Reports Preliminary Clinical Results for Inhaled KB707 in Advanced NSCLC Patients with 27% Objective Response Rate
and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational ...